2024-10-30 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

**Company Overview:** Thermo Fisher Scientific Inc. is a global leader in providing analytical instruments, life sciences solutions, and laboratory products.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** TMO has achieved a cumulative return of **212.99%** compared to the S&P 500 (VOO) with a return of **136.74%**.
* **Outperformance:** TMO has outperformed the S&P 500 by **76.25%** in terms of cumulative return.
* **Relative Outperformance:** TMO's current relative outperformance is in the **35.79th percentile** compared to its historical performance against the S&P 500. This indicates that its current outperformance is above average but not exceptional. 

**2. Recent Price Movements:**

* **Closing Price:** 547.77
* **5-day Moving Average:** 557.71
* **20-day Moving Average:** 588.18
* **60-day Moving Average:** 602.36

The recent price action suggests a short-term downtrend as the price is below all three moving averages. The significant gap between the current price and the 60-day moving average indicates a potential for further downward pressure.

**3. Technical Indicators:**

* **RSI:** 21.96 – The RSI suggests that the stock is currently in the oversold territory, indicating a potential for a rebound in the near term. 
* **PPO:** -0.93 – The PPO indicates a bearish momentum, reinforcing the short-term downtrend.
* **Delta_Previous_Relative_Divergence:** -18.98 – This indicates a significant decline in the relative performance compared to the previous period.
* **Expected Return:** 46.87% - This represents the projected long-term (2+ years) excess return compared to the S&P 500, suggesting potential for strong long-term growth.

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-08-02 | 4.05   | $10.54 B$   |
| 2024-05-03 | 3.47   | $10.35 B$   |
| 2023-11-03 | 4.44   | $10.57 B$   |
| 2023-08-04 | 3.53   | $10.69 B$   |
| 2024-08-02 | 3.53   | $10.69 B$   |

**Analysis:** The latest earnings report for the quarter ending June 30th, 2024, shows a strong performance with EPS beating expectations. Revenue remained consistent with the previous quarters, demonstrating steady growth. 

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter       | Revenue      | Profit Margin |
|------------|--------------|---------------|
| 2024-06-30 | $10.54B      | 41.24%        |
| 2024-03-31 | $10.35B      | 40.65%        |
| 2023-12-31 | $10.89B      | 40.35%        |
| 2023-09-30 | $10.57B      | 40.82%        |
| 2023-06-30 | $10.69B      | 39.78%        |

**Capital and Profitability:**

| Quarter       | Equity       | ROE           |
|------------|--------------|---------------|
| 2024-06-30 | $47.43B      | 3.26%         |
| 2024-03-31 | $45.52B      | 2.92%         |
| 2023-12-31 | $46.73B      | 3.49%         |
| 2023-09-30 | $45.33B      | 3.78%         |
| 2023-06-30 | $43.75B      | 3.11%         |

**Analysis:** The company demonstrates consistent revenue growth and robust profitability, as evidenced by its high profit margins and healthy ROE. This financial stability underscores its strong position in the market.

**6. News and Recent Issues:**

* **Recent Earnings News:** (Please provide specific details on recent earnings releases, available from sources like Shacknews, FINBOLD etc.)
* **Market Outlook:** (Include information about current market sentiment and analyst expectations for the stock. You can refer to FINBOLD for this information.) 
* **Analyst Opinions and Performance Highlights:** (Provide a summary of analyst opinions and highlight significant developments or performance factors. FINBOLD can be helpful for this information.) 

**7. Comprehensive Analysis:**

Thermo Fisher Scientific is a financially stable company with strong market position. Its recent earnings performance and consistent revenue growth demonstrate a healthy growth trajectory. However, the stock has experienced a recent short-term downtrend, indicated by its position below moving averages and negative PPO. Despite the near-term bearish outlook, the company's long-term prospects remain positive, with a high expected return relative to the S&P 500. The oversold RSI suggests a potential for a rebound in the short term. It is important to monitor news and analyst opinions for updates on the company's performance and market sentiment.

**Disclaimer:** This is a general analysis for informational purposes only and should not be considered financial advice. Please conduct your own research and consult a financial professional before making any investment decisions. 
